l 012 has been researched along with dicarbethoxydihydrocollidine in 1 studies
| Studies (l 012) | Trials (l 012) | Recent Studies (post-2010) (l 012) | Studies (dicarbethoxydihydrocollidine) | Trials (dicarbethoxydihydrocollidine) | Recent Studies (post-2010) (dicarbethoxydihydrocollidine) |
|---|---|---|---|---|---|
| 24 | 0 | 10 | 327 | 0 | 119 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brandes, RP; Daiber, A; Förstermann, U; Hink, U; Hortmann, M; Kleschyov, AL; Li, H; Mollnau, H; Mülsch, A; Münzel, T; Oelze, M; Schulz, E; von Sandersleben, A; Wenzel, P | 1 |
1 other study(ies) available for l 012 and dicarbethoxydihydrocollidine
| Article | Year |
|---|---|
Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats.
Topics: Acridines; Adrenergic beta-Antagonists; Angiotensin II; Animals; Benzopyrans; Blood Vessels; Cell Line; Cyclic GMP; Dicarbethoxydihydrocollidine; Endothelium, Vascular; Ethanolamines; Fluorescence; Hemoglobins; Humans; Luminescence; Luminescent Agents; Luminol; Male; Myocardium; NADPH Oxidases; Nebivolol; Nitric Oxide; Nitric Oxide Synthase Type III; Nitrites; Phosphoproteins; rac1 GTP-Binding Protein; Rats; Rats, Wistar; Signal Transduction; Superoxides | 2006 |